Browse Articles

A new therapy against MDR bacteria by in silico virtual screening of Pseudomonas aeruginosa LpxC inhibitors

Liu et al. | Apr 27, 2022

A new therapy against MDR bacteria by <em>in silico</em> virtual screening of <em>Pseudomonas aeruginosa</em> LpxC inhibitors

Here, seeking to address the growing threat of multidrug-resistant bacteria (MDR). the authors used in silico virtual screening to target MDR Pseudomonas aeruginosa. They considered a key protein in its biosynthesis and virtually screened 20,000 candidates and 30 derivatives of brequinar. In the end, they identified a possible candidate with the highest degree of potential to inhibit the pathogen's lipid A synthesis.

Read More...

Herbal formulation, HF1 diminishes tumorigenesis: a cytokine study between MCF-7 and BM-MSCs.

Guru et al. | Apr 11, 2022

Herbal formulation, HF1 diminishes tumorigenesis: a cytokine study between MCF-7 and BM-MSCs.

The authors use HF-1, an herbal formation, on bone marrow derived cells as well as breast cancer cells to assess HF-1's ability to prevent tumorigenesis. As metastasis requires coordination of multiple cells in the tumor microenvironment, their findings that HF-1 augments cytokine expression such as VEGF & TGF-B show that HF-1 has potential application to therapeutics.

Read More...

Phospholipase A2 increases the sensitivity of doxorubicin induced cell death in 3D breast cancer cell models

Lee et al. | Mar 30, 2022

Phospholipase A2 increases the sensitivity of doxorubicin induced cell death in 3D breast cancer cell models

Inefficient penetration of cancer drugs into the interior of the three-dimensional (3D) tumor tissue limits drugs' delivery. The authors hypothesized that the addition of phospholipase A2 (PLA2) would increase the permeability of the drug doxorubicin for efficient drug penetration. They found that 1 mM PLA2 had the highest permeability. Increased efficiency in drug delivery would allow lower concentrations of drugs to be used, minimizing damage to normal cells.

Read More...

Evaluation of platelet-rich plasma vs. platelet lysate: VEGF and PDGF concentration, stability, and shelf life

Prasad et al. | Mar 30, 2022

Evaluation of platelet-rich plasma vs. platelet lysate: VEGF and PDGF concentration, stability, and shelf life

Cell-free biologicals are a novel method of treating clinical conditions which involve chronic inflammation such as tendonitis and osteoarthritis. This study compared platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) in platelet-rich plasma (PRP), activated PRP (aPRP), and platelet lysate (PL). It was hypothesized that PL would contain higher concentrations of growth factors than PRP and that different storage temperatures for PL would diminish cytokine expression. Results demonstrated PL had the highest concentrations of both cytokines, with concentrations slightly diminishing at-80C. aPRP and PRP demonstrated lower concentrations of PDGF and VEGF than PL.

Read More...